

Acute Large Vessel Occlusion

- [Discovery of metabolic biomarkers for distinguishing LAA and SVO subtypes of acute ischemic stroke](#)
- [Quantitative insights into stroke recovery utilizing delayed vessel ratio from color-coded multiphase computed tomography angiography](#)
- [Objective nutritional indices as an independent predictor of functional outcome after endovascular therapy for acute ischemic stroke: a cohort study in a Chinese population](#)
- [Hyperglycaemia does not modify the efficacy of endovascular therapy in the late time window \(6-24 hours\)](#)
- [Beyond Recanalization: Machine Learning-Based Insights into Post-Thrombectomy Vascular Morphology in Stroke Patients](#)
- [Recanalization of Basilar Artery Occlusion during Interhospital Transfer for Thrombectomy](#)
- [The risk of endovascular thrombectomy in acute ischemic stroke patients with large vessel occlusions harboring unruptured intracranial aneurysms](#)
- [Impact of dehydration on endovascular treatment in patients with acute ischemic stroke due to large vessel occlusion](#)

Epidemiology

[Large vessel occlusions](#) (LVOs), variably defined as blockages of the proximal intracranial anterior and posterior circulation, account for approximately 24% to 46% of [acute ischemic strokes](#)

In the USA, around 30% of 795,000 [strokes](#) per year are due to proximal large-vessel occlusion, and these are a major cause of death and disability ¹⁾

[Large Vessel Occlusion](#) was predominant in patients with [acute ischemic stroke in COVID-19 pandemic](#) across 2 continents, occurring at a significantly younger age and affecting [African Americans](#) disproportionately in the [USA](#) ²⁾.

Emergent large [vessel occlusion](#) accounts for 20-40% of [ischemic strokes](#) and is the most debilitating form of [stroke](#).

Etiology

Approximately 10% to 20% of large vessel occlusion (LVO) strokes involve tandem lesions (TLs), defined as concomitant intracranial LVO and stenosis or occlusion of the cervical internal carotid artery.

Complications

[Acute Ischemic Stroke](#).

Guidelines

The current [guideline](#) recommends using an intravenous tissue-type [plasminogen activator](#) (IV tPA) prior to [mechanical thrombectomy](#) (MT) in eligible [acute ischemic stroke](#) (AIS) with emergent large vessel occlusion (ELVO) ³⁾

Treatment

[Large Vessel Occlusion Treatment.](#)

Outcome

[Large vessel occlusion outcome.](#)

Retrospective cohort studies

To analyze the effect of fasting blood glucose levels after reperfusion of acute large vessel occlusion (ALVO) on patient functional prognosis.

Methods: Retrospectively included ALVO patients from three large stroke centers in China, all of whom achieved vascular reperfusion after mechanical thrombectomy or bridging thrombolysis. The prognosis scores of all patients at 90 ± 7 days post-recanalization were categorized into a good prognosis group (mRS 0-2) and a poor prognosis group (mRS 3-6). The relationship between mean blood glucose levels at 72 h post-recanalization and prognosis was explored using multivariable logistic regression analysis. Then we measured the area under the ROC curve for all factors to assess their predictive performance.

Results: (1) Totally 2,056 patients were included in the study, with 1,488 males and 568 females. There were 1,370 patients in the good prognosis group (mRS 0-2) and 686 in the poor prognosis group (mRS 3-6). (2) The two groups exhibited significant differences in terms of age, preoperative mRS score, history of diabetes, and mean fasting blood glucose (MFBG) ($p < 0.001$). (3) With 90-day mRS as the outcome variable, all independent variables were included in Univariate and multivariate regression analyses analysis, and the results showed that: age, preoperative mRS score, history of diabetes, and MFBG are all independent predictors of prognosis after recanalization of ALVO, with MFBG demonstrating a higher predictive power than the other factors (AUC = 0.644).

Conclusion: Various factors are correlated with the prognosis in patients who have undergone ALVO recanalization. Notably, the MFBG level demonstrates a significant predictive value for outcomes within the first 72 h following the recanalization procedure ⁴⁾.

Case series

In a retrospective multicenter study, patients with [anterior circulation large vessel occlusions](#) who

underwent pretreatment non-contrast CT (NCCT) and CT perfusion (CTP), successful [reperfusion](#) (modified Thrombolysis in Cerebral Infarction $\geq 2b$), and post-treatment MRI, were included from three [stroke centers](#). Automated calculation of [ischemic core](#) volumes was obtained on NCCT scans using ML algorithm deployed by e-Stroke Suite and from CTP using Olea software ([Olea Medical](#)). Comparative analysis was performed between estimated core volumes on NCCT and CTP and against MRI calculated final infarct volume (FIV).

A total of 111 patients were included. Estimated ischemic core volumes (mean \pm SD, mL) were 20.4 \pm 19.0 on NCCT and 19.9 \pm 18.6 on CTP, not significantly different ($P=0.82$). There was moderate ($r=0.40$) and significant ($P<0.001$) correlation between estimated core on NCCT and CTP. The mean difference between FIV and estimated core volume on NCCT and CTP was 29.9 \pm 34.6 mL and 29.6 \pm 35.0 mL, respectively ($P=0.94$). Correlations between FIV and estimated core volume were similar for NCCT ($r=0.30$, $P=0.001$) and CTP ($r=0.36$, $P<0.001$).

Results show that ML-based estimated ischemic core volumes on NCCT are comparable to those obtained from concurrent CTP in magnitude and in degree of correlation with MR-assessed final [infarct](#) volume (FIV). ⁵⁾

This study provides valuable insights into the use of ML algorithms to estimate ischemic core volumes in stroke patients using NCCT and CTP scans. However, the study has limitations, including a relatively small sample size, potential biases. While the findings are promising, further research with larger, more diverse samples and a focus on clinical outcomes is necessary to validate the practical utility of these methods in stroke management.

Of 685 patients, 623 (mean [SD] age, 67 [12.2] years; 406 [65.2%] male) were included in the analysis, of whom 363 (58.4%) were in the CAS group and 260 (41.6%) were in the nonstenting group. The [carotid artery stenting](#) (CAS) group had a lower proportion of patients with atrial fibrillation (38 [10.6%] vs 49 [19.2%], $P = .002$), a higher proportion of preprocedural degree of cervical stenosis on digital subtraction angiography (90%-99%: 107 [32.2%] vs 42 [20.5%], $P < .001$) and atherosclerotic disease (296 [82.0%] vs 194 [74.6%], $P = .003$), a lower median (IQR) National Institutes of Health Stroke Scale score (15 [10-19] vs 17 [13-21], $P < .001$), and similar rates of intravenous thrombolysis and stroke time metrics when compared with the nonstenting group. After adjustment for confounders, the odds of favorable functional outcome (adjusted odds ratio [aOR], 1.67; 95% CI, 1.20-2.40; $P = .007$), favorable shift in mRS scores (aOR, 1.46; 95% CI, 1.02-2.10; $P = .04$), and successful reperfusion (aOR, 1.70; 95% CI, 1.02-3.60; $P = .002$) were significantly higher for the CAS group compared with the nonstenting group. Both groups had similar odds of sICH (aOR, 0.90; 95% CI, 0.46-2.40; $P = .87$) and 90-day mortality (aOR, 0.78; 95% CI, 0.50-1.20; $P = .27$). No heterogeneity was noted for 90-day functional outcome and sICH in prespecified subgroups.

In this multicenter, international cross-sectional study, CAS of the cervical lesion during MT was associated with improvement in functional outcomes and reperfusion rates without an increased risk of sICH and mortality in patients with TLs ⁶⁾.

Among 202 patients, 106 (52%) had [ASPECTS](#) 3 or less (mean [SD] age, 76.7 [9.6] years; 54 female individuals [50.9%]) and 96 had ASPECTS 4 to 5 (mean [SD] age, 75.6 [10.6] years; 36 female

individuals [37.5%]). Of patients with ASPECTS 3 or less, 12 (21.4%) in the EVT group and 9 (18.0%) in the no EVT group had an mRS score of 0 to 3 (odds ratio [OR], 1.24; 95% CI, 0.47-3.26). Of patients with ASPECTS 4 to 5, 19 patients (43.2%) in the EVT group and 4 (7.7%) in the no EVT group had an mRS score of 0 to 3 at 90 days (OR, 9.12; 95% CI, 2.80-29.70; interaction P = .01). The ordinal shift across the range of mRS scores toward a better outcome was not significant in those with ASPECTS 3 or less (common OR, 1.56; 95% CI, 0.79-3.10) but was significant in those with ASPECTS 4 to 5 (common OR, 4.48; 95% CI, 2.07-9.71; interaction P = .046). The risk of intracranial hemorrhage was significantly increased in patients with ASPECTS 3 or less when EVT was conducted (OR, 4.14; 95% CI, 1.84-9.32) and nonsignificantly increased in those with ASPECTS 4 to 5 (OR, 2.05; 95% CI, 0.89-4.73; interaction P = .24).

Conclusions and Relevance: In this study, **EVT** was associated with improved 90-day functional outcomes in patients with acute large vessel occlusion stroke and ASPECTS was 4 to 5 but not in those with ASPECTS 3 or less ⁷⁾.

A total of 162 patients (104 men, median age 76 years old) were enrolled. Forty one patients (25%) was **atherosclerotic occlusion**. **Non-culprit stenosis** was frequently observed in the atherosclerotic occlusion group than the embolic occlusion group (68% vs. 26%, P < 0.001). The presence of non-culprit stenosis was independently associated with atherosclerotic occlusion (OR, 11.00; 95% CI, 3.96-30.52; P < 0.001).

In hyperacute **stroke** receiving **endovascular therapy**, **non-culprit stenosis** identification may be needed in order to perform an adequate **revascularization**, especially for atherosclerotic occlusion ⁸⁾.

1)

Giles JA, Vellimana AK, Adeoye OM. Endovascular Treatment of Acute Stroke. *Curr Neurol Neurosci Rep.* 2022 Jan 31. doi: 10.1007/s11910-022-01168-9. Epub ahead of print. PMID: 35098425.

2)

Khandelwal P, Al-Mufti F, Tiwari A, Singla A, Dmytriw AA, Piano M, Quilici L, Pero G, Renieri L, Limbucci N, Martínez-Galdámez M, Schüller-Arteaga M, Galván J, Arenillas-Lara JF, Hashim Z, Nayak S, Desousa K, Sun H, Agarwalla PK, Nanda A, Roychowdhury JS, Nourollahzadeh E, Prakash T, Gandhi CD, Xavier AR, Lozano JD, Gupta G, Yavagal DR. Incidence, Characteristics and Outcomes of **Large Vessel Stroke** in **COVID-19 Cohort: An International Multicenter Study**. *Neurosurgery.* 2021 Mar 18;nyab111. doi: 10.1093/neuros/nyab111. Epub ahead of print. PMID: 33734404.

3)

Kolahchi Z, Rahimian N, Momtazmanesh S, Hamidianjahromi A, Shahjouei S, Mowla A. Direct Mechanical Thrombectomy Versus Prior Bridging Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. *Life (Basel).* 2023 Jan 9;13(1):185. doi: 10.3390/life13010185. PMID: 36676135; PMCID: PMC9863165.

4)

Luo B, Xiang Y, Meng F, Wang Y, Zhang Z, Ren H, Ma L. Impact of fasting blood glucose on prognosis after acute large vessel occlusion reperfusion: results from a multicenter analysis. *Front Neurol.* 2024 Oct 23;15:1422851. doi: 10.3389/fneur.2024.1422851. PMID: 39507628; PMCID: PMC11537856.

5)

Shahrouki P, Kihira S, Tavakkol E, Qiao JX, Vagal A, Khatri P, Bahr-Hosseini M, Colby GP, Jahan R, Duckwiler G, Szeder V, Ledbetter L, Cai S, Salehi B, Doshi AH, Belani P, Fifi JT, De Leacy R, Mocco J, Saver JL, Liebeskind DS, Nael K. Automated assessment of ischemic core on non-contrast computed tomography: a multicenter comparative analysis with CT perfusion. *J Neurointerv Surg.* 2023 Nov 2;jnis-2023-020954. doi: 10.1136/jnis-2023-020954. Epub ahead of print. PMID: 37918907.

6)

Farooqui M, Zaidat OO, Hassan AE, Quispe-Orozco D, Petersen N, Divani AA, Ribo M, Abraham M, Fifi J,

Guerrero WR, Malik AM, Siegler JE, Nguyen TN, Sheth S, Yoo AJ, Linares G, Janjua N, Galecio-Castillo M, Tekle WG, Ringheanu VM, Oliver M, Dawod G, Kobsa J, Prasad A, Ikram A, Lin E, Below K, Zevallos CB, Gadea MO, Qureshi A, Dajles A, Matsoukas S, Rana A, Abdalkader M, Salazar-Marioni S, Soomro J, Gordon W, Vivanco-Suarez J, Turabova C, Mokin M, Yavagal DR, Jumaa MA, Ortega-Gutierrez S. Functional and Safety Outcomes of Carotid Artery Stenting and Mechanical Thrombectomy for Large Vessel Occlusion Ischemic Stroke With Tandem Lesions. *JAMA Netw Open*. 2023 Mar 1;6(3):e230736. doi: 10.1001/jamanetworkopen.2023.0736. PMID: 36857054.

7)

Uchida K, Shindo S, Yoshimura S, Toyoda K, Sakai N, Yamagami H, Matsumaru Y, Matsumoto Y, Kimura K, Ishikura R, Yoshida A, Inoue M, Beppu M, Sakakibara F, Shirakawa M, Morimoto T; RESCUE-Japan LIMIT Investigators. Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion: A Secondary Analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT). *JAMA Neurol*. 2022 Oct 10. doi: 10.1001/jamaneurol.2022.3285. Epub ahead of print. PMID: 36215044.

8)

Sakuta K, Yaguchi H, Kida H, Sato T, Miyagawa S, Mitsumura H, Fuga M, Ishibashi T, Okuno K, Murayama Y, Iguchi Y. The meaning of non-culprit stenosis in hyperacute stroke with large vessel occlusion. *J Neurol Sci*. 2022 Mar 30;436:120247. doi: 10.1016/j.jns.2022.120247. Epub ahead of print. PMID: 35381404.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=acute_large_vessel_occlusionLast update: **2025/07/04 11:59**